Pay in 4 interest-free payments of $11.25 Learn more
Ships within 48 hours · Estimated delivery Aug 2 - Aug 7
PI3K-alpha (IC50=0
CD8+ T cell depletion abrogates the efficacy of CPI-444 treatment as a single agent as well as in combination with anti-PD-L1
CPI-637 inhibits MYC expression in AMO-1 cells (EC50 = 0
PubMed PMID: 15860572
KPT-330 - CAS# 1393477-72-9 009 PI3K-alpha (IC50=0KPT 330, CAS No. 1393477 72 9, is an orally bioavailable, potent and selective XPO1 CRM1 Inhibitor. KPT 330 is effective in acquired resistance to ibrutinib and synergizes with ibrutinib in chronic lymphocytic leukemia. KPT 330 potentiates the antitumor activity of gemcitabine in human pancreatic cancer through inhibition of tumor growth, depletion of the antiapoptotic proteins, and induction of apoptosis. KPT 330 has strong activity against primary
US$ 160.00
US$ 174.50
US$ 4450.00
US$ 180.00
US$ 199.00
US$ 99.00
US$ 1743.50
US$ 180.00